The study is held by Prime Medicine, Inc., and is structured as an open-label, single-arm, multicenter Phase 1/2 study testing the efficacy and safety of the transplantation of ex vivo-modified prime-edited autologous CD34+ stem cells (PM359) in autosomal recessive Chronic Granulomatous Disease (CGD) caused by NCF1 (Neutrophil Cytosolic Factor 1) gene mutations (NCT06559176). The gene discussed is CD34; the disease is chronic granulomatous disease.